Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Adult human mesenchymal stem cell as a target for neoplastic transformation


The neoplastic process may involve a cancer stem cell. This concept has emerged largely from the careful analysis of tumour biopsy systems from haematological, breast and brain tumours. However, the experimental systems necessary to provide the cellular and molecular evidence to support this important concept have been lacking. We have used adult mesenchymal stem cells (hMSC) transduced with the telomerase hTERT gene to investigate the neoplastic potential of adult stem cells. The hTERT-transduced line, hMSC-TERT20 at population doubling level (PDL) 256 showed loss of contact inhibition, anchorage independence and formed tumours in 10/10 mice. hMSC-TERT4 showed loss of contact inhibition at PDL 95, but did not exhibit anchorage independence and did not form tumours in mice. Both lines had a normal karyotype but showed deletion of the Ink4a/ARF locus. At later passage, hMSC-TERT4 also acquired an activating mutation in KRAS. In hMSC-TERT20, expression of the cell cycle-associated gene, DBCCR1 was lost due to promoter hypermethylation. This epigenetic event correlated with acquisition of tumorigenicity. These data suggest that the adult hMSCs can be targets for neoplastic transformation and have implications for the development of novel anticancer therapeutics and for the use of hMSC in tissue engineering and transplantation protocols.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others


  • Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF . (2003). Proc. Natl. Acad. Sci. USA, 100, 3983–3988.

  • Collas P and Hakelien AM . (2003). Trends Biotechnol., 21, 354–361.

  • Dick JE . (2003). Proc. Natl. Acad. Sci. USA, 100, 3547–3549.

  • Gronbaek K, de Nully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Moller P, Zeuthen J and Guldberg P . (2000). Leukemia, 14, 1727–1735.

  • Hahn WC and Meyerson M . (2001). Ann Med., 33, 123–129.

  • Hahn WC and Weinberg RA . (2002). N. Engl. J. Med., 347, 1593–1603.

  • Hamad NM, Banik SS and Counter CM . (2002). Oncogene, 21, 7121–7125.

  • Helman LJ and Meltzer P . (2003). Nat. Rev. Cancer, 3, 685–694.

  • Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M and Kornblum HI . (2003). Proc. Natl. Acad. Sci. USA, 100, 15178–15183.

  • Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA and Verfaillie CM . (2002). Nature, 418, 41–49.

  • Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA and Klingelhutz AJ . (1998). Nature, 396, 84–88.

  • Korbling M and Estrov Z . (2003). N. Engl. J. Med., 349, 570–582.

  • Lessard J and Sauvageau G . (2003). Nature, 423, 255–260.

  • Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, Olsen JC, Miller SW, Weinberg RA and Hahn WC . (2002). Oncogene, 21, 4577–4586.

  • Mackall CL, Meltzer PS and Helman LJ . (2002). Cancer Cell, 2, 175–178.

  • Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC and Rotter V . (2003). Cancer Res., 63, 7147–7157.

  • Nishiyama H, Gill JH, Pitt E, Kennedy W and Knowles MA . (2001). Oncogene, 20, 2956–2964.

  • Owens DM and Watt FM . (2003). Nat. Rev. Cancer, 3, 444–451.

  • Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ and Clarke MF . (2003). Nature, 423, 302–305.

  • Passegue E, Jamieson CH, Ailles LE and Weissman IL . (2003). Proc. Natl. Acad. Sci. USA, 100 (Suppl 1), 11842–11849.

  • Perez-Losada J and Balmain A . (2003). Nat. Rev. Cancer, 3, 434–443.

  • Preston SL, Alison MR, Forbes SJ, Direkze NC, Poulsom R and Wright NA . (2003). Mol. Pathol., 56, 86–96.

  • Reya T, Morrison SJ, Clarke MF and Weissman IL . (2001). Nature, 414, 105–111.

  • Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG and Wang CY . (2002). Nat. Biotechnol., 20, 587–591.

  • Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG and Kassem M . (2002). Nat. Biotechnol., 20, 592–596.

  • Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB . (2003). Cancer Res., 63, 5821–5828.

  • Wang J, Hannon GJ and Beach DH . (2000). Nature, 405, 755–756.

Download references


We thank Drs Steen Kølvraa, Charlotte B Sørensen and Thomas J Corydon for critical readings of the manuscript. This study was supported by grants from Danish Medical Research Council, Danish Center for Stem Cell Research, the Novo Nordisk foundation and Danish Cancer Society.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Nedime Serakinci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Serakinci, N., Guldberg, P., Burns, J. et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23, 5095–5098 (2004).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links